ALT
Altimmune, Inc.
$2.73
+0.74%
$530.9M
No data for this timeframe.
Vol
Market Cap$530.9M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (80%)
Inst. Holders7 funds
Inst. Value$48.7M
Inst. Activity4 buys / 1 sells
Insider Activity5B / 0S
Insider Net $$198.4K
Reddit Sentiment33° Cool
SEC Reports10
Press Releases5
Recent Activity
Jun 3, 2026
short_volume
Short Volume: ALT — 58.4% short (1.0M / 1.6M)
Short: 951,954 | Exempt: 0 | TRF Vol: 1,629,206 | Short Ratio: 58.4% | Off-exchange volume (dark poo
May 13, 2026
SEC
Altimmune reported Q1 2026 results with a net loss of $0.18 per share, narrower than the $0.26 loss in Q1 2025, but the
8-K — Impact 4/10
May 13, 2026
SEC
Altimmune reported Q1 2026 EPS of -$0.18, beating the -$0.25 consensus estimate by 28%, though revenue was $0 (vs $1K co
PRESS-RELEASE — Impact 5/10
May 6, 2026
SEC
Altimmune announced it will report Q1 2026 financial results on May 13, 2026. The press release contains no financial re
PRESS-RELEASE — Impact 2/10
May 1, 2026
Insider
SAYARE MITCHEL sold 48,800 shares
Director @ $0.00 ($0.00)
May 1, 2026
Insider
GILL JOHN sold 48,800 shares
Director @ $0.00 ($0.00)
May 1, 2026
Insider
Hodges Philip sold 48,800 shares
Director @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — ADD
9,491,159 shares ($34.3M)
Price Targets
$16.06
+503.6% upside
Strong Buy
Current $2.66
Low $2.50
Median $18.00
High $28.00
9 analysts
$2.50
$28.00
Analyst Ratings
3Strong Buy
9Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 14, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Mar 16, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 6, 2026 | B. Riley Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.16 | $-0.22 — $-0.10 | 41% YoY | 6 |
| Next Q | $-0.18 | $-0.24 — $-0.11 | 16% YoY | 6 |
| Current FY | $-0.74 | $-0.96 — $-0.52 | 26% YoY | 6 |
| Next FY | $-0.90 | $-1.25 — $-0.56 | -22% YoY | 6 |
Latest Reports
BULLISH
Press
7/10
Altimmune presented new 48-week data from the IMPACT Phase 2b trial of pemvidutide in MASH at the EASL Congress 2026. Th
May 28, 2026
NEUTRAL
8-K
4/10
Altimmune reported Q1 2026 results with a net loss of $0.18 per share, narrower than the $0.26 loss in Q1 2025, but the
May 13, 2026
NEUTRAL
PRESS-RELEASE
5/10
Altimmune reported Q1 2026 EPS of -$0.18, beating the -$0.25 consensus estimate by 28%, though revenue was $0 (vs $1K co
May 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $34.3M | ADD |
| MORGAN STANLEY | $4.9M | ADD |
| TWO SIGMA INVESTMENTS, LP | $4.6M | TRIM |
| FMR LLC | $2.0M | ADD |
| BANK OF AMERICA CORP | $1.4M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | SAYARE MITCHEL | A | $0.00 |
| May 1, 2026 | GILL JOHN | A | $0.00 |
| May 1, 2026 | Hodges Philip | A | $0.00 |
| May 1, 2026 | Pisano Wayne | A | $0.00 |
| May 1, 2026 | Schafer Klaus | A | $0.00 |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
7 institutional holders with $48.7M total value (13,489,554 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, TWO. Net buying activity: 4 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 9,491,159 | $34.3M | 70.4% | ADD +48.9% |
| 2 | MORGAN STANLEY | 1,359,885 | $4.9M | 10.1% | ADD +78.5% |
| 3 | TWO SIGMA INVESTMENTS, LP | 1,265,683 | $4.6M | 9.4% | TRIM -36.6% |
| 4 | FMR LLC | 564,093 | $2.0M | 4.2% | ADD +26.7% |
| 5 | BANK OF AMERICA CORP /DE/ | 383,783 | $1.4M | 2.8% | TRIM -55.2% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 283,669 | $1.0M | 2.1% | ADD +38.7% |
| 7 | WELLS FARGO & COMPANY/MN | 141,282 | $510.0K | 1.0% | ADD +52.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 6,373,638 | 9,491,159 | +48.9% | $34.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 1,996,848 | 1,265,683 | -36.6% | $4.6M | 2025-Q4 |
| FMR LLC | ADD | 445,137 | 564,093 | +26.7% | $2.0M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 204,449 | 283,669 | +38.7% | $1.0M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 92,907 | 141,282 | +52.1% | $510.0K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 437,286 | 1,996,848 | +356.6% | $7.5M | 2025-Q3 |
| MORGAN STANLEY | ADD | 835,407 | 1,491,049 | +78.5% | $5.6M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 716,019 | 320,440 | -55.2% | $1.2M | 2025-Q3 |
| MORGAN STANLEY | ADD | 657,247 | 835,407 | +27.1% | $3.2M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 280,552 | 716,019 | +155.2% | $2.8M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 1,147,816 | 437,286 | -61.9% | $1.7M | 2025-Q2 |
| FMR LLC | DOUBLED | 20,803 | 401,843 | +1831.7% | $1.6M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | ADD | 605,303 | 1,147,816 | +89.6% | $5.7M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 921,822 | 657,247 | -28.7% | $3.3M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 1,280,144 | 568,700 | -55.6% | $2.8M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | TRIM | 215,538 | 91,681 | -57.5% | $458.4K | 2025-Q1 |
| FMR LLC | TRIM | 56,739 | 20,803 | -63.3% | $104.0K | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 949,287 | 1,280,144 | +34.9% | $9.2M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 1,295,585 | 921,822 | -28.8% | $6.6M | 2024-Q4 |
| UBS Group AG | DOUBLED | 282,455 | 719,555 | +154.8% | $5.2M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 127,329 | 215,538 | +69.3% | $1.6M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 211,626 | — | $1.3M | 2024-Q3 |
13 unique insiders with 5 transactions. Net insider value: $198.4K ($198.4K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | SAYARE MITCHEL | Director | A | 48,800 | $0.00 | $0.00 |
| May 1, 2026 | GILL JOHN | Director | A | 48,800 | $0.00 | $0.00 |
| May 1, 2026 | Hodges Philip | Director | A | 48,800 | $0.00 | $0.00 |
| May 1, 2026 | Pisano Wayne | Director | A | 48,800 | $0.00 | $0.00 |
| May 1, 2026 | Schafer Klaus | Director | A | 48,800 | $0.00 | $0.00 |
| May 1, 2026 | Jorkasky Diane | Director | A | 48,800 | $0.00 | $0.00 |
| May 1, 2026 | Sohn Catherine A. | Director | A | 48,800 | $0.00 | $0.00 |
| May 1, 2026 | Lawver Teri L | Director | A | 48,800 | $0.00 | $0.00 |
| Apr 6, 2026 | GILL JOHN | Director | BUY | 9,200 | $3.41 | $31.3K |
| Apr 1, 2026 | Durso Jerome Benedict | President and CEO | BUY | 15,000 | $3.14 | $47.1K |
| Apr 1, 2026 | WEAVER GREGORY L | Chief Financial Officer | BUY | 10,000 | $3.15 | $31.5K |
| Mar 6, 2026 | WEAVER GREGORY L | Chief Financial Officer | BUY | 5,000 | $3.54 | $17.7K |
| Mar 6, 2026 | Durso Jerome Benedict | President and CEO | BUY | 20,000 | $3.54 | $70.8K |
| Feb 26, 2026 | Roberts M Scot | Chief Scientific Officer | A | 95,430 | $0.00 | $0.00 |
| Feb 26, 2026 | Roberts M Scot | Chief Scientific Officer | A | 222,670 | $0.00 | $0.00 |
| Feb 26, 2026 | WEAVER GREGORY L | Chief Financial Officer | A | 259,000 | $0.00 | $0.00 |
| Feb 26, 2026 | WEAVER GREGORY L | Chief Financial Officer | A | 111,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Roberts M Scot | Chief Scientific Officer | M | 7,775 | $0.00 | $0.00 |
| Feb 2, 2026 | Roberts M Scot | Chief Scientific Officer | F | 2,329 | $5.55 | $12.9K |
| Feb 2, 2026 | Roberts M Scot | Chief Scientific Officer | M | 7,775 | $0.00 | $0.00 |
| Jan 31, 2026 | Roberts M Scot | Chief Scientific Officer | A | 5,567 | $3.07 | $17.1K |
| Jan 31, 2026 | Jordt Raymond M | Chief Business Officer | A | 4,571 | $3.07 | $14.0K |
| Jan 31, 2026 | Garg Vipin K | Director | A | 6,926 | $3.07 | $21.3K |
| Jan 30, 2026 | Roberts M Scot | Chief Scientific Officer | M | 9,275 | $0.00 | $0.00 |
| Jan 30, 2026 | Roberts M Scot | Chief Scientific Officer | F | 2,859 | $5.60 | $16.0K |
| Jan 30, 2026 | Roberts M Scot | Chief Scientific Officer | M | 9,275 | $0.00 | $0.00 |
| Jan 30, 2026 | Garg Vipin K | Director | M | 26,775 | $0.00 | $0.00 |
| Jan 30, 2026 | Garg Vipin K | Director | F | 11,632 | $5.60 | $65.1K |
| Jan 30, 2026 | Garg Vipin K | Director | M | 26,775 | $0.00 | $0.00 |
10 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 9 neutral. Avg impact: 4.4/10.
NEUTRAL
8-K
4/10
Altimmune reported Q1 2026 results with a net loss of $0.18 per share, narrower than the $0.26 loss
May 13, 2026
NEUTRAL
PRESS-RELEASE
5/10
Altimmune reported Q1 2026 EPS of -$0.18, beating the -$0.25 consensus estimate by 28%, though reven
May 13, 2026
NEUTRAL
PRESS-RELEASE
2/10
Altimmune announced it will report Q1 2026 financial results on May 13, 2026. The press release cont
May 6, 2026
NEUTRAL
8-K
5/10
Altimmune is raising $211.5 million through a public offering of 64.25 million shares of common stoc
Apr 24, 2026
NEUTRAL
424B5
5/10
Altimmune is raising $211.5 million through a public offering of 64.25 million shares of common stoc
Apr 24, 2026
NEUTRAL
424B5
5/10
Altimmune is conducting a follow-on public offering of common stock, pre-funded warrants, and common
Apr 22, 2026
NEUTRAL
CLUSTER
3/10
Three corporate insiders at Altimmune, Inc. purchased shares in the open market over a 7-day period,
Apr 6, 2026
NEUTRAL
CLUSTER
4/10
Two top executives at Altimmune — the CEO and CFO — collectively purchased $79K worth of stock in ea
Apr 1, 2026
NEUTRAL
CLUSTER
4/10
Altimmune's CEO and CFO collectively purchased $88,490 worth of shares in open-market transactions o
Mar 9, 2026
BULLISH
8-K
7/10
Altimmune reported financial results for Q4 and full year 2025, highlighted by a 7% reduction in net
Mar 5, 2026
BULLISH
7/10
Altimmune presented new 48-week data from the IMPACT Phase 2b trial of pemvidutide in MASH at the EA
May 28, 2026
NEUTRAL
2/10
Altimmune announced management participation in upcoming investor conferences, a routine corporate e
May 27, 2026
BULLISH
6/10
Altimmune announced that its 48-week IMPACT Phase 2b data for pemvidutide in MASH has been selected
May 13, 2026
BEARISH
7/10
Altimmune announced the pricing of a public offering of common stock and pre-funded warrants, along
Apr 23, 2026
BULLISH
8/10
Altimmune reported its Q4 and full-year 2025 financial results, highlighted by a strengthened balanc
Mar 5, 2026
Current analyst consensus: Strong Buy (80% buy). Based on 15 analysts: 3 strong buy, 9 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$16.06 mean target
+503.6% upside
Strong Buy (1.60)
$2.50 Low
$28.00 High
| Metric | Value |
|---|---|
| Current Price | $2.66 |
| Target Low | $2.50 |
| Target Mean | $16.06 |
| Target Median | $18.00 |
| Target High | $28.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.16 | $-0.22 | $-0.10 | 40.7% | — | 6↑ 0↓ | $0.0B | -68.8% | 6 |
| Next Q 2026-09-30 |
$-0.18 | $-0.24 | $-0.11 | 15.9% | — | 6↑ 0↓ | $0.0B | -68.8% | 6 |
| Current FY 2026-12-31 |
$-0.74 | $-0.96 | $-0.52 | 26.0% | — | 6↑ 0↓ | $0.0B | -88.9% | 6 |
| Next FY 2027-12-31 |
$-0.90 | $-1.25 | $-0.56 | -21.9% | — | 6↑ 0↓ | $0.0B | -100.0% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.160 | |
| 7d ago | $-0.160 | |
| 30d ago | $0.000 | -0.160 |
| 60d ago | $-0.259 | +0.099 |
| 90d ago | $-0.283 | +0.123 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 14, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Mar 16, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 6, 2026 | B. Riley Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 9 | 3 | 0 | 0 | 80% | |
| May 1, 2026 | 3 | 9 | 3 | 0 | 0 | 80% | |
| Apr 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| Mar 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| Feb 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| Jan 1, 2026 | 3 | 8 | 2 | 1 | 0 | 79% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Earnings play
▲ 1
💬 1
⚡ 0.5
Jun 3, 2026
short_volume
Short Volume: ALT — 58.4% short (1.0M / 1.6M)
Short: 951,954 | Exempt: 0 | TRF Vol: 1,629,206 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
May 28, 2026
fda
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
<p align="center"><em>“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with
May 27, 2026
fda
Altimmune to Participate in Upcoming Investor Conferences
<p align="left">GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=7-Z5xYGuWSfHFnGLTQMosLYNgxTW
May 19, 2026
Clinical Trial
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
Phase Phase 2 — COMPLETED
May 13, 2026
earnings
Altimmune Announces First Quarter 2026 Financial Results and Business Update
<p align="center"><em>Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026</em></p>
May 13, 2026
fda
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
<p align="center"><em>Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in “Best of EASL 2026” by EASL</em><
May 13, 2026
earnings_calendar
ALT Q1 2026 Earnings Before Market Open — 2026-05-13
May 7, 2026
earnings_calendar
ALT Q1 2026 Earnings Before Market Open — 2026-05-07
May 6, 2026
earnings
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
<p align="justify">GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=S7Fb0rQYRHd89JAHkwDYAC-r2
Apr 30, 2026
short_volume
Short Volume: ALT — 55.4% short (1.9M / 3.4M)
Short: 1,905,071 | Exempt: 0 | TRF Vol: 3,436,496 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: ALT — 63.5% short (1.6M / 2.5M)
Short: 1,616,710 | Exempt: 8,346 | TRF Vol: 2,546,964 | Short Ratio: 63.5% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
short_volume
Short Volume: ALT — 58.4% short (1.8M / 3.0M)
Short: 1,764,406 | Exempt: 161 | TRF Vol: 3,018,994 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: ALT — 60.9% short (3.9M / 6.4M)
Short: 3,894,595 | Exempt: 216,639 | TRF Vol: 6,399,570 | Short Ratio: 60.9% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
offering
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
<p align="justify">GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=eyrgv02seuEx013pn1dsfDa
Apr 23, 2026
short_volume
Short Volume: ALT — 63.7% short (10.0M / 15.7M)
Short: 9,998,203 | Exempt: 599,761 | TRF Vol: 15,704,910 | Short Ratio: 63.7% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
offering
Altimmune Announces Proposed Underwritten Public Offering of Securities
<p align="justify">GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=NueRmSZp_xj1mwkEhZduwwq